{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:55:37Z","timestamp":1787028937093,"version":"build-2736575974"},"reference-count":15,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Systemic inflammation plays a critical role in cancer progression and prognosis. The Systemic Inflammation Response Index (SIRI), a novel marker integrating neutrophil, monocyte, and lymphocyte counts, has been suggested as a prognostic indicator in various malignancies. This study aimed to evaluate the prognostic significance of SIRI in patients with metastatic pancreatic cancer receiving first-line chemotherapy. Materials and Methods: This retrospective study included 147 patients with metastatic pancreatic cancer who received first-line chemotherapy or best supportive care between 2010 and 2024. Clinical and laboratory data were collected from medical records. Overall survival (OS) and progression-free survival (PFS) were assessed using the Kaplan\u2013Meier method, and prognostic factors were identified by univariate and multivariate Cox regression analyses. Results: The median OS and PFS were 7 and 4 months, respectively. Multivariate analysis revealed that ECOG \u2265 2 (HR: 2.094, p = 0.019), liver metastasis (HR: 2.039, p = 0.027), and each unit increase in SIRI (HR: 1.156, p &lt; 0.001) were independent predictors of poorer OS. Patients with SIRI &gt; 1.86 had significantly shorter OS compared to those with SIRI \u2264 1.86 (median OS: 4 vs. 9 months, p = 0.019). Conclusions: SIRI is an independent prognostic marker for survival in metastatic pancreatic cancer patients undergoing first-line and subsequent lines of chemotherapy. These inflammation-based markers are simple, cost-effective tools that could be integrated into routine clinical practice to aid in risk assessment and treatment planning.<\/jats:p>","DOI":"10.3390\/medicina61112020","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T10:56:47Z","timestamp":1762945007000},"page":"2020","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["SIRI as a Prognostic Marker in Metastatic Pancreatic Cancer"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7082-2542","authenticated-orcid":false,"given":"Hikmet","family":"Akar","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Manisa Celal Bayar University, Manisa 45030, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9317-942X","authenticated-orcid":false,"given":"Ferhat","family":"Ekinci","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Manisa Celal Bayar University, Manisa 45030, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4859-7574","authenticated-orcid":false,"given":"Atike P\u0131nar","family":"Erdo\u011fan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Manisa Celal Bayar University, Manisa 45030, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1857-593X","authenticated-orcid":false,"given":"Mustafa","family":"\u015eahbazlar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Manisa Celal Bayar University, Manisa 45030, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2021.06.027","article-title":"Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis","volume":"520","author":"Cai","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_2","first-page":"209","article-title":"Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"73","author":"Sung","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2129884","DOI":"10.1080\/08941939.2022.2129884","article-title":"Pancreatic Cancer: A Review of Current Treatment and Novel Therapies","volume":"36","author":"Kolbeinsson","year":"2022","journal-title":"J. Investig. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s11864-021-00895-4","article-title":"Systemic Therapy for Metastatic Pancreatic Cancer","volume":"22","author":"Ettrich","year":"2021","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e23486","DOI":"10.1097\/MD.0000000000023486","article-title":"Prognostic value of the systemic inflammation response index in human malignancy: A meta-analysis","volume":"99","author":"Wei","year":"2020","journal-title":"Medicine"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"671811","DOI":"10.3389\/fonc.2021.671811","article-title":"The prognostic value of preoperative Systemic Inflammatory Response Index (SIRI) in patients with high-grade glioma and the establishment of a nomogram","volume":"11","author":"He","year":"2021","journal-title":"Front Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"15593258211064744","DOI":"10.1177\/15593258211064744","article-title":"Systemic Inflammation Response Index as a Prognostic Marker in Cancer Patients: A Systematic Review and Meta-Analysis of 38 Cohorts","volume":"19","author":"Zhou","year":"2021","journal-title":"Dose Response"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1016\/S1470-2045(14)70263-3","article-title":"Cancer-related inflammation and treatment effectiveness","volume":"15","author":"Diakos","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_9","first-page":"862","article-title":"Research advances on the value of preoperative systemic inflammatory response index in predicting the prognosis of patients with resectable pancreatic cancer","volume":"57","author":"Jia","year":"2019","journal-title":"Zhonghua Wai Ke Za Zhi."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1007\/s12032-012-0226-8","article-title":"Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer","volume":"29","author":"Wang","year":"2012","journal-title":"Med. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1002\/cncr.30057","article-title":"A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy","volume":"122","author":"Qi","year":"2016","journal-title":"Cancer"},{"key":"ref_12","first-page":"1001","article-title":"Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients","volume":"85","author":"Onodera","year":"1984","journal-title":"Nihon Geka Gakkai Zasshi"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ctrv.2012.08.003","article-title":"The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer","volume":"39","author":"McMillan","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2398725","DOI":"10.1080\/07853890.2024.2398725","article-title":"Prognostic value of neutrophil to lymphocyte ratio in patients with advanced pancreatic ductal adenocarcinoma treated with systemic chemotherapy","volume":"56","author":"Kitsugi","year":"2024","journal-title":"Ann. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7338","DOI":"10.1245\/s10434-023-13781-0","article-title":"Prognostic Impact of Tumor Markers (CEA and CA19-9) on Patients with Resectable Colorectal Liver Metastases Stratified by Tumor Number and Size: Potentially Valuable Biologic Markers for Preoperative Treatment","volume":"30","author":"Kobayashi","year":"2023","journal-title":"Ann. Surg. Oncol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/11\/2020\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T11:34:33Z","timestamp":1762947273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/11\/2020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":15,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["medicina61112020"],"URL":"https:\/\/doi.org\/10.3390\/medicina61112020","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]}}}